SSY Group Limited announced that China’s National Medical Products Administration has approved both the drug production and registration of two type 3 chemical injections—Multiple Electrolytes, Sodium Acetate and Glucose Injection (250 ml and 500 ml) and Metoclopramide Hydrochloride Injection (2 ml:10 mg). The approvals confirm that the products have passed the national generic-drug consistency evaluation.
Multiple Electrolytes, Sodium Acetate and Glucose Injection is indicated for replenishing and maintaining water-electrolyte balance and supplying energy when oral intake is impossible or inadequate.
Metoclopramide Hydrochloride Injection serves as an antiemetic for chemotherapy-, radiotherapy-, surgery-, or drug-induced vomiting; symptomatic relief of nausea and vomiting in conditions such as acute gastroenteritis, biliary and pancreatic diseases, and uremia; and pre-diagnostic procedures including duodenal intubation and barium gastrointestinal examinations. The preparation approval follows the Group’s February 2026 registration approval for the corresponding bulk drug.
The Board described the disclosure as a voluntary update intended to keep shareholders and potential investors informed of the Group’s latest product-development progress.
Comments